You are here

  • Home
  • Archive
  • Volume 11, Issue 10
  • First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors

 

Online download statistics by month:

Online download statistics by month: October 2023 to January 2026

AbstractFullPdf
Oct 202337383
Nov 2023461463135
Dec 2023334340127
Jan 2024187191103
Feb 202414114154
Mar 202417317695
Apr 202414915384
May 202414815170
Jun 202413013363
Jul 202422322783
Aug 2024156157100
Sep 202412212440
Oct 202413813948
Nov 202417117468
Dec 202415415655
Jan 202514014761
Feb 202526626672
Mar 202515615758
Apr 2025170170104
May 202516616883
Jun 2025909147
Jul 2025330
Sep 2025110
Jan 2026110
Total371737671553